Axxcess Wealth Management LLC Purchases 1,529 Shares of Natera, Inc. $NTRA

Axxcess Wealth Management LLC raised its position in shares of Natera, Inc. (NASDAQ:NTRA) by 49.0% during the second quarter, HoldingsChannel reports. The fund owned 4,651 shares of the medical research company’s stock after acquiring an additional 1,529 shares during the quarter. Axxcess Wealth Management LLC’s holdings in Natera were worth $786,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its position in Natera by 0.6% during the first quarter. Vanguard Group Inc. now owns 12,393,827 shares of the medical research company’s stock valued at $1,752,611,000 after acquiring an additional 77,357 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Natera by 56.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock valued at $1,490,144,000 after acquiring an additional 3,795,315 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Natera by 9.9% in the first quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company’s stock worth $1,041,055,000 after purchasing an additional 660,538 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Natera by 13.7% in the first quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company’s stock worth $287,908,000 after purchasing an additional 245,719 shares during the last quarter. Finally, Maverick Capital Ltd. grew its holdings in shares of Natera by 19.7% in the first quarter. Maverick Capital Ltd. now owns 1,634,769 shares of the medical research company’s stock worth $231,173,000 after purchasing an additional 268,715 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of research analyst reports. Stephens restated an “overweight” rating and issued a $183.00 price target on shares of Natera in a report on Friday, August 15th. Wells Fargo & Company initiated coverage on shares of Natera in a report on Monday, September 22nd. They issued an “equal weight” rating and a $175.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a report on Wednesday, October 8th. Canaccord Genuity Group restated a “buy” rating and issued a $200.00 price target on shares of Natera in a report on Tuesday. Finally, Royal Bank Of Canada set a $268.00 price target on shares of Natera and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and an average target price of $196.81.

Natera Price Performance

NASDAQ:NTRA opened at $181.69 on Friday. Natera, Inc. has a 1-year low of $117.27 and a 1-year high of $187.34. The company has a 50-day moving average of $168.19 and a 200 day moving average of $158.35. The firm has a market cap of $24.94 billion, a PE ratio of -95.13 and a beta of 1.74.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business had revenue of $546.60 million during the quarter, compared to analysts’ expectations of $476.84 million. During the same period last year, the company earned ($0.30) earnings per share. The firm’s revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Buying and Selling at Natera

In other Natera news, CFO Michael Burkes Brophy sold 2,491 shares of the stock in a transaction dated Tuesday, September 30th. The shares were sold at an average price of $162.05, for a total transaction of $403,666.55. Following the completion of the sale, the chief financial officer directly owned 69,189 shares of the company’s stock, valued at approximately $11,212,077.45. This represents a 3.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider John Fesko sold 678 shares of the stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $155.46, for a total transaction of $105,401.88. Following the sale, the insider directly owned 152,747 shares of the company’s stock, valued at approximately $23,746,048.62. The trade was a 0.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 72,464 shares of company stock valued at $10,963,125. 5.63% of the stock is currently owned by corporate insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.